Sufentanil Intranasal

• Status: Recruiting
• Trial end date: 2025-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Study of the effects of intranasal sufentanil on patients presenting to the emergency department with acute post-traumatic pain.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Universitaire Saint Pierre
• Treatments: Sufentanil

Criteria

Inclusion Criteria:

• posttraumatic pain + lasting for less than 24 hours + with an analog visual pain scale of 7/10 or more

Exclusion Criteria:

• pregnant

• <18 years

• prisoners

• lesions of head, face or abdomen

• no consent given or possible

• pain not scorable

• known drug abuse or substitution therapy

• chronic level 3 pain medication

• intake of level 3 < 8 hours

• intoxicated patient

• allergy or intolerance to opiates

• renal or hepatic insufficiency

• < 50kg body weight

• hemodynamic instability